Skip to site services

Skip to top navigation

Skip to left navigation

Skip to site tools

Skip to main content

Alert service | Downloads | Glossary | Print this page

2001

Register for our Alert Service if you would like to be alerted when a news release is added to the site.

2004
Date	Title
10 Nov 2004	Interim Results for six months ended 30th September 2004
25 Jun 2004	Vectura announces successful completion of IPO
02 Jun 2004	Vectura and SkyePharma form strategic alliance for pulmonary delivery technologies
26 May 2004	Vectura announces second successful clinical study on erectile dysfunction product
17 May 2004	Arakis and Vectura announce positive data from Phase IIa trial of COPD drug

2003
Date	Title
13 Oct 2003	Vectura CSO awarded West Technology Entrepreneur of the Year
18 Aug 2003	Arakis and Vectura announces Phase IIa trial for COPD drug
21 Jul 2003	Vectura announces positive data from clinical trial on its treatment for erectile dysfunction
25 Mar 2003	Vectura's novel erectile dysfunction treatment enters clinical trials in Europe

2002
Date	Title
04 Dec 2002	Vectura and GlaxoSmithKline sign dry powder drug formulation deal
06 Jun 2002	Vectura and Zambon complete licensing deal
11 Feb 2002	Vectura acquires rights to a novel Dry Powder Inhaler device

2001
Date	Title
12 Jul 2001	Chiesi and Vectura extend collaboration in pMDI field
05 Jun 2001	Vectura and Ranbaxy to collaborate on a novel oral controlled-released system
24 Apr 2001	Vectura completes £10.55 Million financing to advance drug delivery programmes
30 Mar 2001	Vectura announces appointment of Jack Cashman to the position of Non-Executive Chairman of its Board of Directors

2000
Date	Title
29 Nov 2000	Vectura and Arakis collaborate to develop a novel inhaled treatment for COPD
23 May 2000	Vectura and Chiesi to develop inhaled HFA systems for systemic drug delivery

1999
Date	Title
18 Aug 1999	Vectura acquires Co-ordinated Drug Development Ltd and assumes responsibility for the Centre for Drug Formulation Studies, to create 30-strong R&D team
24 Feb 1999	Vectura Ltd. receives £1.75 million from the Merlin Fund LP, the dedicated bioscience venture capital fund